Published:
Bioinformatics Expert Dr. Jiaan Yang Joins Sundia MediTech With Innovative PFSC Technology
SHANGHAI , July 6 /PRNewswire-Asia/ -- Sundia MediTech Company, a leading
integrated pharmaceutical and biotech R&D outsourcing company in Shanghai,
China announced today that Sundia has acquired Protein Folding Shape Code
(PFSC) technology for doing probe binding site for drug discovery from
Microtech Nano LLC, a R&D Company in Indianapolis, IN , USA. As a part of this
business deal, Dr. Jiaan Yang, the founder and President of Microtech Nano LLC
joins Sundia as Vice President of Drug Discovery Technology.
Dr. Yang was trained as a physical chemist. In his 26 year professional
career in pharmaceutical, biotech and nanotechnology industries in USA, he
accumulated a broad range of experience in bioinformatics with expertise in
theoretical chemistry, quantum chemistry, computational chemistry, molecular
biology and computer information technology.
In recent years, Dr. Yang quit his job from Eli Lilly and devoted 3 years
to research and to develop an innovative method to describe protein complex 3D
structure, and achieved PFSC, an outstanding success. For a long time, it has
been a great challenge to protein chemists and biologists how to obtain a
complete description of protein 3D structure, including the irregular shapes
of loops and coils. With his expertise in multiple fields, Dr. Yang applied
mathematics on this biology subject, generated a set of Protein Folding Shape
Code (PFSC) for a complete description of protein's complex 3D structure, and
developed computer software to process protein data. The success of PFSC is a
big scientific breakthrough in structural biology research.
Sundia's Chairman and CEO Dr. Xiaochuan Wang commented that "the
application of PFSC technology will bring a great impact to pharmaceutical
research and drug discovery." According to her, the PFSC is able to
effectively screen protein 3D structure database, probe new indications,
explore potential side effects, and help better understanding drug and disease
mechanisms on a molecular level and quantitative assessment for ligand-binding
site to assist drug design.
"With PFSC, Sundia can serve our client companies new drug discovery needs
more effectively. Scientists like Dr. Yang, who has a solid scientific skill
set, as well as a strong business mindset and entrepreneurial spirit will
greatly enhance our CRO service level," said Dr. Xiaochuan Wang.
Dr. Yang holds a Ph.D. degree in physical chemistry from Louisiana State
University in USA, supervised by Dr. Neil Kestner. He also received a M.S.
degree from Theoretical Chemistry Institute,Jilin University inChina, with
Professor Tang Aoqing.
About Sundia: Sundia MediTech Company is a leading integrated
pharmaceutical contract research organization (CRO) company based inShanghai,
China, to provide R&D outsourcing services to biotech and pharmaceutical
companies worldwide, ranging from early hit screening, biological service,
lead optimization, DMPK, candidate preclinical development, formulation
development, API manufacture, and regulatory submission. For more information,
please visit http://www.sundia.com .
SOURCE Sundia MediTech Company
Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,HEA,BIO,MTC,PHA,PER,PDT,Sundia-MediTech-PFSC
Search News
Daily News
